Antineoplastic Agents TRIZ Cases
- Urolithin Metabolites for Cancer Treatment via Patient Classification
Pharmaceutical compositions containing urolithins treat neoplastic diseases through anti-proliferative and pro-apoptotic activities.
- BRAF and MEK Inhibitor Combination Therapy for Cancer
Combining BRAF and MEK inhibitors minimizes paradoxical MAPK activation in wild-type tumors.
- RTK Fusion Inhibitor and MMP Inhibitor Combination for Cancer Resistance
Dual inhibition of RTK fusion proteins and matrix metalloproteases increases cell death rates, overcoming resistance to single-agent therapies.
- Rhenium(I) Complexes for Platinum-Resistant Cancer Treatment
Rhenium(I) complexes overcome platinum resistance and toxicity by inducing ER stress while enabling real-time imaging of drug distribution.
- Liposomal Imipramine Blue Delivery for Glioma Inhibition
Sub-200 nm liposomes cross the blood-brain barrier to inhibit glioma invasion and metastasis.
- GAB1 Inhibitors Overcome PI3K/AKT Pathway Compensation in Hematological Malignancies
Co-administering GAB1 inhibitors with BTK blockers prevents PI3K/AKT pathway compensation, overcoming treatment resistance in hematological malignancies.
- Oriental Medicine Co-Administration with Anticancer Agents
Co-administering oriental medicine formulations with anticancer agents reduces toxicity and drug resistance while enhancing tumor inhibition.
- Cytarabine-Modified miRNA Mimics for AML Treatment
Cytarabine-modified miRNA mimics replace cytosine nucleosides to inhibit DNA synthesis and reduce toxicity in acute myeloid leukemia treatment.
- Multi-Agent Therapy for Drug-Tolerant Glioblastoma Stem Cells
Targets drug-tolerant glioblastoma stem cells by merging three inhibitor pathways to overcome therapeutic resistance mechanisms.
- MET and VEGFR2 Inhibition for Ocular Melanoma Treatment
Compound 1 suppresses MET and VEGFR2 signaling to induce apoptosis, addressing ineffective metastatic ocular melanoma treatments.
- lncGRS-1 Targeting for Glioma Radiotherapy Sensitization
CRISPRi screening identifies lncGRS-1 as a target, enabling antisense oligonucleotides that enhance radiotherapy efficacy while sparing normal brain tissue.